KRTX - Karuna Therapeutics Inc Stock Price, Fair Value and News

329.83USD Market Closed

Market Summary

USD329.83

Market Closed

KRTX Stock Price

View Fullscreen

KRTX RSI Chart

KRTX Valuation

Market Cap

12.6B

Price/Earnings (Trailing)

-29.05

Price/Sales (Trailing)

247.43

EV/EBITDA

-28.78

Price/Free Cashflow

-32.41

KRTX Price/Sales (Trailing)

KRTX Profitability

EBT Margin

-850.37%

Return on Equity

-34.58%

Return on Assets

-32.46%

Free Cashflow Yield

-3.09%

KRTX Fundamentals

KRTX Revenue

Revenue (TTM)

50.9M

KRTX Earnings

Earnings (TTM)

-433.7M

Earnings Growth (Yr)

-49.35%

Earnings Growth (Qtr)

4.45%

Breaking Down KRTX Revenue

Last 7 days

3.1%

Last 30 days

2.8%

Last 90 days

50.1%

Trailing 12 Months

74.2%

How does KRTX drawdown profile look like?

KRTX Financial Health

Current Ratio

19.31

KRTX Investor Care

Shares Dilution (1Y)

10.67%

Diluted EPS (TTM)

-11.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	21.7M	37.9M	50.9M	0
2022	30.4M	23.8M	17.2M	10.6M
2021	2.1M	1.4M	19.2M	37.0M
2020	3.5M	4.1M	4.0M	3.3M
2019	0	0	0	2.5M
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Karuna Therapeutics Inc

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

CEO	Mr. William Meury
WEBSITE	karunatx.com
INDUSTRY	Biotechnology
EMPLOYEES	210

Karuna Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Karuna Therapeutics Inc? What does KRTX stand for in stocks?

KRTX is the stock ticker symbol of Karuna Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Karuna Therapeutics Inc (KRTX)?

As of Mon Mar 18 2024, market cap of Karuna Therapeutics Inc is 12.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRTX stock?

You can check KRTX's fair value in chart for subscribers.

Is Karuna Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KRTX is over valued or under valued. Whether Karuna Therapeutics Inc is cheap or expensive depends on the assumptions which impact Karuna Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRTX.

What is Karuna Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 18 2024, KRTX's PE ratio (Price to Earnings) is -29.05 and Price to Sales (PS) ratio is 247.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRTX PE ratio will change depending on the future growth rate expectations of investors.